actin filament associated protein 1 like 2Genealiases: CTB-1144G6.4 · KIAA1914 · XB130
Q-omics provides the consensus-scored AFAP1L2 profile across patient tissues and cancer cell-line models. AFAP1L2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AFAP1L2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, AFAP1L2 protein abundance shows 21,258 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UVM, KIRC, and UCEC as cancer lineages where AFAP1L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AFAP1L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AFAP1L2 survival associations across molecular data types. AFAP1L2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AFAP1L2 RNA expression–survival associations across cancer types. High AFAP1L2 expression shows unfavorable associations in UVM and KIRP, but favorable associations in ESCA, KIRC, BRCA and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AFAP1L2 RNA expression.
This table summarizes AFAP1L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AFAP1L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AFAP1L2 shows lower tumor expression in KIRC, KICH, THCA, KIRP and UCEC and higher tumor expression in HNSC. The KIRC box plot shows higher AFAP1L2 RNA expression in normal versus tumor tissue (log2 FC = −2.001, t-test p < 0.001).
This table shows molecular features associated with AFAP1L2 in patient tissues and cancer cell lines. In patient samples, AFAP1L2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, AFAP1L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and PANCREAS.
